Piramal Pharma Limited

NSE PPLPHARMA.NS

Piramal Pharma Limited Gross Profit Margin for the year ending March 31, 2024: 60.08%

Piramal Pharma Limited Gross Profit Margin is 60.08% for the year ending March 31, 2024, a -2.82% change year over year. Gross Profit Ratio is the ratio of gross profit to net sales, indicating the percentage of revenue that exceeds the cost of goods sold and reflects the efficiency of a company in managing its production or procurement and sales.

Piramal Pharma Limited Gross Profit Margin for the year ending March 31, 2023 was 61.83%, a 23.77% change year over year.
Piramal Pharma Limited Gross Profit Margin for the year ending March 31, 2022 was 49.95%, a -11.59% change year over year.
Piramal Pharma Limited Gross Profit Margin for the year ending March 31, 2021 was 56.50%.

Key data

Date	Gross Profit Margin	Operating Income Margin	EBT Margin	Net Income Margin

NSE: PPLPHARMA.NS

Piramal Pharma Limited

CEO	Mr. Peter Daniel DeYoung
IPO Date	Oct. 19, 2022
Location	India
Headquarters	507, Skyline Wealth Space
Employees	6,719
Sector	Health Care
Industries Pharmaceuticals Drugstores & Retail Pharmacies

Description

Piramal Pharma Limited operates as a pharmaceutical company. It sells a portfolio of pharma products, as well as provides various pharma services, including injection, HPAPI, etc. The company was incorporated in 2020 and is based in Mumbai, India. Piramal Pharma Limited operates as a subsidiary of Piramal Enterprises Limited.

Key trends

Past 5 years